The role of myocardial collagen network in hypertensive heart disease

Current Hypertension Reviews

Volumn 3, Issue 1, 2007, Pages 1-7

  Díez, Javier ^a,b,d   López, Begoña ^a   González, Arantxa ^a   Querejeta, Ramón ^c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c HOSPITAL DONOSTIA   (Spain)

^d NONE   (Spain)

Author keywords

Collagen; Fibrosis; Heart failure; Hypertensive heart disease

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOGENIC FACTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BINDING PROTEIN; COLLAGEN FIBER; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; CYSTEINE RICH ANGIOGENIC INDUCER 61 PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; LOSARTAN; MEMBRANE TYPE 1 MATRIX METALLOPROTEINASE CYTOPLASMIC TAIL BINDING PROTEIN 1; PERINDOPRIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; UNCLASSIFIED DRUG; VASODILATOR AGENT;

BIOASSAY; CARDIOVASCULAR RISK; DIASTOLE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSIVE HEART DISEASE; IMAGING SYSTEM; ISCHEMIC HEART DISEASE; MOLECULAR GENETICS; NON INVASIVE MEASUREMENT; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; SYSTOLE;

EID: 34247147972     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340207779815509     Document Type: Review

References (72)

1. Van der Rest M, Bruckner P. Collagens: diversity at the molecular and supramolecular levels. Curr Opin Struct Biol 1993; 3: 430-6.
2. Vuorio E, De Crombugghe B. The family of collagen genes. Annu Rev Biochem 1990; 59: 837-72.
3. Van der Rest M, Garone R. Collagen family of proteins. FASEB J 1991; 5: 2814-23.
4. Koch M, Foley JE, Hahn R et al. Alpha 1 (XX) collagen, a new member of the collagen subfamily, fibril-associated collagens with interrupted triple helices. J Biol Chem 2001; 276: 23120-6.
5. Medugoriac I. Characterization of intramural collagen in the mammalian left ventricle. Basic Res Cardiol 1982; 77: 589-98.
6. Mukherjee D, Sen S. Alteration of collagen phenotypes in ischemic cardiomyopathy. J Clin Invest 1991; 88: 1141-6.
7. Eghbali K Czaja MJ, Zeydel M et al. Collagen mRNAs in isolated adult heart cell. J Mol Cell Cardiol 1988; 20: 267-76.
8. Eghbali M, Blumenfeld OO, Seifter S et al. Localization of types I, III and IV collagen mRNAs in rat heart cells by in situ hybridization. J Mol Cell Cardiol 1989; 21: 103-13.
9. McAnultry RJ, Laurent GJ. Collagen synthesis and degradation in vivo. Evidence for rapid rates of collagen turnover with extensive degradation of newly synthesized collagen in tissues of the adult rat. Collagen Relat Res 1987; 7: 93-104.
10. Monfort I, Perez-Tamayo R. The distribution of collagenase in normal rat tissues. J Histochem Cytochem 1975; 23: 910-20.
11. Cleutjens JPM, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1994; 27: 1281-92.
12. Coker ML, Doscher MA, Thomas CV, Galis ZS, Spinale FG. Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol Heart Circ Physiol 1999; 277: H777-87.
13. Tyagi SC, Matsubara L, Weber KT. Direct extraction and estimation of collagenase(s) activity by zymography in microquantities of rat myocardium and uterus. Clin Biochem 1993; 26: 191-8.
14. Weber KT. Angiotensin II and connective tissue: homeostasis and reciprocal regulation. Regul Pept 1999; 82: 1-17.
15. Burlew BS, Weber KT. Connective tissue and the heart. Functional significance and regulatory mechanisms. Cardiol Clin 2000; 18: 435-42.
16. Weber KT. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 1989; 13: 1637-52.
17. Terracio L, Rubin T, Gullberg D et al. Expression of collagen binding integrins during cardiac development and hypertrophy. Circ Res 1991; 68: 734-44.
18. Tanaka M, Fujiwara H, Onodera T et al. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 1986; 55: 575-81.
19. Olivetti G, Melissari M, Balbi T et al. Myocyte cellular hypertrophy is responsible for ventricular remodeling in the hypertrophied heart of middle aged individuals in the absence of cardiac failure. Cardiovasc Res 1994; 28: 1199-208.
20. Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 1998; 16: 1031-41.
21. Ciulla M, Paliotti R, Hess DB et al. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: Endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr 1997; 10: 657-64.
22. Schwartzkopff B, Brehm K Mundhenke M et al. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 2000; 36: 220-5.
23. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart discase. Circulation 2000; 102: 1388-93.
24. Querejeta R, Varo N, López B et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000; 101: 1729-35.
25. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000; 15: 264-72.
26. Díez J, González A, López B, Querejeta R. Mechanism of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nat Clin Pract Cardiovasc Med 2005; 2: 209-16.
27. MacKenna DA, Vaplon SM, McCulloch AD. Microstructural model of perimysial collagen fibers for resting myocardial mechanics during ventriculair filling. Am J Physiol 1997; 273: H1576-86.
28. Burlew BS, Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz 2002; 27: 92-8.
29. Wu Y, Tobias AH, Bell K et al. Cellular and molecular mechanism of systolic and diastolic dysfunction in an avian model of dilated cardiomyopathy. J Mol Cell Cardiol 2004;37: 111-19.
30. Ohsata K, Shimizu M, Sugihara M et al. Histopathologic factors related to diastolic function in myocardial hypertrohy. Jpn Circ J 1992; 56: 325-33.
31. Diez J, Querejeta R, López B et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffess in hypertensive patients. Circulation 2002; 105: 2512-7.
32. McLenachan JM, Dargie JH. Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relation to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens 1990; 3: 735-40.
33. Querejeta R, López B, González A et al. Increased collagan type I synthesis in patients with heart failure of hypertensive origin. Circulation 2004; 110: 1263-8.
34. López B, González A, Querejeta R, Larman M, Díez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 2006; 48: 89-96.
35. Schwartzkopff B, Motz W, Frenzel H et al. Structural and functional alterations of the intramyocardial coronary arterioles in patiens with arterial hypertension. Circulation 1993; 88: 993-1003.
36. Isoyama S, Ito N, Satoh U et al. Collagen deposition and the reversal of coronary reserve in cardiac hypertrophy. Hypertension 1992; 20: 491-500.
37. Bethge C, Motz W, von Hehm A, Strauer BE. Ventricular arrhythmias in hypertensive heart disease with and without heart failure. J Cardiovasc Pharmacol 1987; 10(suppl 6): S119-28.
38. Nattel S, Shiroshita-Takeshita A, Cardin S, Pelletier P. Mechanism of atrial remodelling and clinical relevance. Curr Opin Cardiol 2005; 20: 21-5.
39. Nattel S. Defining "culprit mechanism" in arrhythmogenic cardiac remodeling. Circ Res 2004; 94: 1403-5.
40. Spach MS, Dolber PC, Heidlage JF. Interaction of inhomogeneities of repolarization with anisotropic propagation in dog atria. A mechanism for both preventing and initiating reentry. Circ Res 1989; 65: 1612-31.
41. Kerut EK, Given M, Giles TD. Review of methods for texture analysis of myocardium from echocardiographic images: a means of tissue characterization. Echocardiography 2003; 20: 727-36.
42. Ciulla M, Paliotti R, Hess DB et al. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: Endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr 1997; 10: 657-64.
43. Picano E, Pelosi G, Marzilli M et al. In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans. Circulation 1990; 81: 58-64.
44. Tandri H, Saranathan M Rodriguez R et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol 2005; 45: 98-103.
45. Díez J, Panizo A, Gil MJ et al. Serum markers of collagen type I metabolism in spontaneously hypertensive rats: relation to myocardial fibrosis. Circulation 1996; 93: 1026-32.
46. López B, Querojeta R, Varo N et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104: 286-91.
47. Guidelines Committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
48. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991; 83: 1771-9.
49. Varo N, Etayo JC, Zalba G et al. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 1999; 17: 107-14.
50. 1, blackade stimulates extracellular collagen type I degradation, and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 2000; 35: 1197-202.
51. Zannad F, Alla F, Dousset B et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales investigators. Circulation 2000; 102: 2700-6.
52. Hayashi M, Tsutamoto T, Wada A et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003; 107: 2559-65.
53. Dechend R, Fiebeler A, Park JK et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Circulation 2001; 104: 576-81.
54. Hasegawa H, Yamamoto R, Takano H et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol 2003; 35: 953-60.
55. Bezerra DG, Mandarim-de-Lacerda CA. Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodeling and glomeruli loss of spontaneously hypertensive rats. Clin Sci 2005; 108: 349-55.
56. Porter KE, Turner NA, O'Regan DJ et al. Sumvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovasc Res 2004; 61: 745-55.
57. Kagitani S, Ueno H, Hirade S et al. Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/ macrophage infiltration in DOCA/salt hypertensive rats. J Hypertens 2004; 22: 1007-15.
58. Rasoul S, Carretero OA, Peng H et al. Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension. J Hypertens 2004; 22: 593-603.
59. Ogata T, Miyauchi T, Sakai S et al. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferators-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 2004; 43: 1481-8.
60. Iglarz M Touyz R, Viel MC et al Peroxisome proliferator-activated receptor-α and receptor-γ activators prevent cardiac fibrosis in mineralocortioid-depeadent hypertension. Hypertension 2003; 42[part 2]: 737-43.
61. Diep QN, Benkirane K, Amiri F et al. PPARα activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol 2004; 36:295-304.
62. Ogata T, Miyauchi T, Sakai S et al. Stimulation of peroxisome-proliferator-activated receptor α (PPARα) attenuates cardiac fibrosis and endothelin-I production in pressure-overloaded rat hearts. Clin Sci 2002; 103(suppl 48): 284S-8S.
63. Meiners S, Hocher B. Weller A et al. Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Circulation 2004; 44: 471-7.
64. Turner ST, Boerwinkle E. Genetics of hypertension, target-organ complications, and response to therapy. Circulation 2000; 102: IV40-5.
65. Formage M, Doris PA. Genomics and epigenomics of hypertension. Curr Opin Mol Ther 2006; 8: 206-14.
66. Goikoetxea MJ, Beaumont J, Zalba G et al. Microarray gene expression profile in the transition from left ventricular hypertrophy to heart failure in hypertensive patients (submitted).
67. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH. CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol 2000; 32: 1805-19.
68. Chen CC, Mo FE, Lau LF. The angiogenic factor. Cyr61 activates a genetic program for wound healing in human skin fibroblasts. J Biol Chem 2001; 276: 47329-37.
69. Uekita T, Gotoh I, Kinoshita T et al. Membrane-type 1 matrix metalloproteinase cytoplasmic tail-binding protein-1 is a new member of the Cupin superfamily. A possible multifunctional protein acting as an invasion suppressor down-regulated in tumors. J Biol Chem 2004; 279: 12734-43.
70. Ocaranza MP, Diaz-Araya G, Carreno JE et al. Polymorphism in gone coding for ACE determines different development of myocardial fibrosis in rats. Am J Physiol Heart Circ Physiol 2004; 286: H498-506.
71. Takahashi T, Ueno H, Yasamoto K et al. Angiotensin-converting enzyme-gene polymorphism is associated with collagen type I synthesis and QT dispersion in essential hypertension. J Hypertens 2003; 21: 985-91.
72. 1 receptor gene is associated with collagea type I synthesis and myocardial stiffness in hypertensives. J Hypertens 2003; 21: 2085-92.